AmpliPhi Biosciences Corporation (APHB)

NYSE MKT - NYSE MKT Real Time Price. Currency in USD
1.52+0.14 (+10.14%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.38
Bid1.11 x 1000
Ask1.55 x 100
Day's Range1.35 - 1.56
52wk Range1.15 - 9.00
1y Target EstN/A
Market Cap16.9M
P/E Ratio (ttm)-0.60
Avg Vol (3m)158,184
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research22 hours ago

    APHB: Early Signs of Efficacy Seen in Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis

    AmpliPhi Biosciences Corp. (APHB) is developing bacteriophage therapeutics for the treatment of bacterial infections. The company’s pipeline consists of treatments that specifically target infections caused by Staphylococcus aureus (AB-SA01), Pseudomonas aeruginosa (AB-PA01), and Clostridium difficile (AB-CD01). Bacteriophages are viruses that infect, replicate in, and kill bacterial cells while not harming eukaryotic cells.

  • Business Wire11 days ago

    AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced an update on the progress of its ongoing Phase 1 clinical trial for the treatment of S.

  • Capital Cube16 days ago

    ETF’s with exposure to AmpliPhi Biosciences Corp. : September 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to AmpliPhi Biosciences Corp. Here are 5 ETF’s with the largest exposure to APHB-US. Comparing the performance and risk of AmpliPhi Biosciences Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)